Nodular lymphocyte predominant Hodgkin's lymphoma

Nodular LPHL is a pathologic diagnosis distinct from cHL. Its unique pathology contributes to a more indolent clinical behavior than cHL. Although management strategies initially overlapped with therapies recommended for cHL, a growing interest in this unique disease process has led to several prospective clinical trials, particularly in early-stage NLPHL. This has allowed for treatment recommendations for NLPHL to become further defined following an evidence-based approach. Rituximab and radiation therapy have emerged as key components in therapy. Through our study of outcomes of NLPHL patients we have also been able to further define the delayed recurrences that can occur as well as the biologic transformations to TCR-LBCL and DLBCL. Further research is particularly important to increase our understanding of the biological factors that influence transformation as well as the best therapeutic regimens for the treatment of advanced NLPHL as well as NLPHL that has transformed to TCR-LBCL or DLBCL. It is hoped that a continued growth of research in NLPHL will allow us to better stratify treatment approaches and thus improve both short-term and long-term outcomes for the NLPHL patients.